Risk Warning & Pitfall Avoidance: Avoid Expired Nose Spray Glucagon Pitfalls
Abstract: Expired nasal glucagon poses critical risks in hypoglycemia emergencies, as peptide degradation reduces efficacy and stability. Market trends show rising demand for stable, room-temperature-stable glucagon analogs (e.g., Eli Lilly’s Baqsimi vs. Xeris’s Gvoke). Key pitfalls include ignoring expiration dates, improper storage (heat/humidity), and lack of potency verification. Technical advantages of intranasal delivery (rapid absorption, no injection) are offset by shorter shelf-life and variable bioavailability. Brands differ in excipient composition (e.g., cyclodextrin-based vs. non-aqueous formulations). Regulatory compliance (FDA/EMA) and lot-specific certificates are essential. Best practices: verify expiration, check cold-chain logistics, and prioritize manufacturers with stability data.